##plugins.themes.academic_pro.article.main##
Abstract
Toxoplasma gondii is an opportunistic pathogen that can kill congenitally infected fetuses, newborns, and immunocompromised patients by reactivating a latent infection. The aim of study knowing the extent of Toxoplasma effect of on the level of IL-17 in SLE patient. In this study, 250 blood samples from both genders female and male were collected. Using the ELISA technique, T. gondii immunoglobulins (IgG and IgM) antibodies and (IL-17) levels were assessed in all serum samples. According to the findings of this investigation, SLE patients had the greatest rate of toxoplasmosis infection. The percentage of anti-Toxoplasma IgG (50%) was higher than the percentage of anti-Toxoplasma IgM (4%), across all groups. IL-17 was highly in SLE and Toxoplasma infected patient (151.87 ± 5.99). These result is suggested that direct pro-inflammatory activity, may have a role in SLE pathogenesis. Toxoplasmosis must be diagnosed and treated in SLE patients in order to lessen the impact of the illness because most immunocompromised people are exposed to a number of possible risk factors, including Toxoplasma original infection or reactivation
Keywords
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
- [1] T. Street, “Transmisibles Comunes Al Hombre,” Control, no. 580, pp. 53–72, 2003.
- [2] R. A. F. BELL, “Nelson. Textbook of Pediatrics.,” Arch. Dis. Child., vol. 76, no. 4, pp. 385–385, 1997, doi: 10.1136/adc.76.4.385d.
- [3] C. T. Weaver, R. D. Hatton, P. R. Mangan, and L. E. Harrington, “IL-17 family cytokines and the expanding diversity of effector T cell lineages,” Annu. Rev. Immunol., vol. 25, pp. 821–852, 2007, doi: 10.1146/annurev.immunol.25.022106.141557.
- [4] S. Aggarwal and A. L. Gurney, “IL-17: prototype member of an emerging cytokine family.,” J. Leukoc. Biol., vol. 71, no. 1, pp. 1–8, 2002, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/11781375
- [5] A. Peck and E. D. Mellins, “Precarious balance: Th17 cells in host defense,” Infect. Immun., vol. 78, no. 1, pp. 32–38, 2010, doi: 10.1128/IAI.00929-09.
- [6] J. Alcocer-Varela and D. Alarcon-Segovia, “Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus,” J. Clin. Invest., vol. 69, no. 6, pp. 1388–1392, 1982, doi: 10.1172/JCI110579.
- [7] E. Bettelli et al., “Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238, 2006, doi: 10.1038/nature04753.
- [8] Alexander, J. and Hunter, C. A. 1998. Immunoregulation during toxoplasmosis. Chem. Immunol., 70:81–102
- .[9] M. Al-Jebouri, M. Al-Janabi, and H. Ismail, “The prevalence of toxoplasmosis among female patients in Al-Hawija and Al-Baiji Districts in Iraq,” Open J. Epidemiol., vol. 03, no. 02, pp. 85–88, 2013, doi: 10.4236/ojepi.2013.32013.
- [10] A. Abdul-Aziz and K. Zghair, “Study of Epidemiology of Toxoplasmosis in Hemodialysis Patients in Baghdad Hospitals,” Ijs.Scbaghdad.Edu.Iq, vol. 55, no. 3, pp. 1236–1242, 2014, [Online]. Available: http://ijs.scbaghdad.edu.iq/issues/Vol55/No3/Vol55Y2014No3BP1236-1242.pdf
- [11] M. Oskoie and C. Lo, “ch Ar of,” vol. 20, pp. 109–120, 2007.
- [12] B. Alshakir, R. H. Kuba, and K. H. Zghair, “Relationship between Toxoplasmosis and Diabetic Pregnant Women,” Indian J. Public Heal. Res. Dev., no. May, 2020, doi: 10.37506/ijphrd.v11i4.9183.
- [13] S. Shivalli and S. Kaup, “Comment on ‘ Toxoplasma gondii Infection in Pregnant Women: A Seroprevalence and Case-Control Study in Eastern China,’” Biomed Res. Int., vol. 2016, pp. 2–4, 2016, doi: 10.1155/2016/5412168.
- [14] A. Molan, K. Nosaka, M. Hunter, and W. Wang, “Seroprevalence and associated risk factors of Toxoplasma gondii infection in a representative Australian human population: The Busselton health study,” Clin. Epidemiol. Glob. Heal., vol. 8, no. 3, pp. 808–814, 2020, doi: 10.1016/j.cegh.2020.02.005.
- [15] R. A. Malek, R. Wassef, E. Rizk, H. Sabry, N. Tadros, and A. Boghdady, “Toxoplasmosis an overlooked disease: Seroprevalence in cancer patients,” Asian Pacific J. Cancer Prev., vol. 19, no. 7, pp. 1987–1991, 2018, doi: 10.22034/APJCP.2018.19.7.1987.
- [16] N. E. S. Mostafa, E. F. A. Hamed, H. E. S. Rahed, S. Y. Mohamed, M. Abdelgawad, and A. M. Elasbali, “The relationship between toxoplasmosis and different types of human tumors,” J. Infect. Dev. Ctries., vol. 12, no. 2, pp. 137–141, 2018, doi: 10.3855/jidc.9672.
- [17] N. K. Tektook, H. H. Al-Janabi, and O. M. Shakir, “Molecular and Immunological test for detection of Toxoplasma gondii in pregnant women and patients with prostate cancer,” Ann. Trop. Med. Public Heal., vol. 23, no. 7, pp. 5–10, 2020, doi: 10.36295/ASRO.2020.23716.
- [18] J. C. Crispín et al., “Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys,” J. Immunol., vol. 181, no. 12, pp. 8761–8766, 2008, doi: 10.4049/jimmunol.181.12.8761.
- [19] C. K. Wong, L. C. W. Lit, L. S. Tam, E. K. M. Li, P. T. Y. Wong, and C. W. K. Lam, “Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity,” Clin. Immunol., vol. 127, no. 3, pp. 385–393, 2008, doi: 10.1016/j.clim.2008.01.019.
- [20] W. CK, H. CY, L. EK, and L. CWK, “Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus,” Lupus, vol. 9, pp. 589–593, 2000.
- [21] B. Stockinger, “Good for Goose, but Not for Gander: IL-2 Interferes with Th17 Differentiation,” Immunity, vol. 26, no. 3, pp. 278–279, 2007, doi: 10.1016/j.immuni.2007.03.001.